

Attachment 11: PLCO Manuscripts, Books & Book Chapters

1. Ahn J, Albanes D, Peters U, Schatzkin A, Lim U, Freedman M, Chatterjee N, Andriole GL, Leitzmann MF, Hayes RB; Prostate, Lung, Colorectal and Ovarian Trial Project Team. Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev, 2007, 16(12):2623-2630.
2. Albertsen PC. The Prostate cancer conundrum, Journal of the National Cancer Institute, July 2003, 95 (13) (editorial), 930-931.
3. Alexander FE, Andriole GL, Aus G, Auvinen A, Beensterboer P, Blijenberg BG, Bonardi R, Buys S, Candas B, Ciatto S, Crawford ED, Demers R, de Koning HJ, Denis L, Dijk MA, Figueiredo F, Gelmann EP, Gohagan J, Hakama M, Hugosson J, Kirkels WI, Krane R, van der Kwast TH, Lilja H, Maattanen L, Mandel J, Miller AB, Moneiro H, Nelen V, Oberman A, Paez A, Prorok PC, Reding D, Rietbergen JWBW, Rose DB, Sanchez AB, Schroder FH, da Silva EC, Simpson N, Smith PH, Stadaert B, Stenman UH, Teppo L, Turkes A, Weissfeld JL, Yokochi L (The International Prostate Screening Trial Evaluation Group) Review: rationale for randomised trials of prostate cancer screening, The International Journal of Cancer, 1999, 35 (2), 262-271.
4. Ali IU, Luke BT, Dean M, Greenwald P. Allelic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. British Journal of Cancer, 2005, 93, 953-959.
5. Andriole GL, Reding D, Hayes RB, Prorok PC, Gohagan JK. The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: status and promise, Urologic Oncology: Seminars and Original Investigations, July-August 2004, 22 (4), 358-361.
6. **Andriole GL, Levin DL, Crawford D, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlan G, Ragard LW, Clapp JD, Prorok PC, Gohagan JK. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial, Journal of the National Cancer Institute, March 2005, 97 (6), 433-438.**
7. Auvinen A, Rietbergen JBW, Denis LJ, Schroder FH, Prorok PC. Prospective evaluation plan for randomised trials of prostate cancer screening. Journal of Medical Screening, 1996, 3, 97-104.
8. Baker SG and Kramer BS. Estimating the cumulative risk of a false positive under a regimen involving types of cancer screening tests. Journal of Medical Screening, 15(1), 18-22, 2008.
9. Berndt SI, Chatterjee N, Huang WY, Chanock SJ, Welch R, Crawford ED, Hayes RB. Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiology Biomarkers and Prevention, January 2007, 16 (1):165-168.
10. Berndt SI, Huang WY, Fallin MD, Helzlsouer KJ, Platz EA, Weissfeld JL, Church TR, Welch R, Chanock SJ, Hayes RB. Genetic variation in base excision repair genes and the prevalence of advanced colorectal adenoma. Cancer Research, February 2007, 67 (3):1395-1404.

11. Berndt SI, Huang WY, Chatterjee N, Yeager M, Welch R, Chanock SJ, Weissfeld JL, Schoen RE, Hayes RB. Transforming growth factor beta 1 (TGFB1) gene polymorphisms and risk of advanced colorectal adenoma. Carcinogenesis, Sept 2007, 28(9) 1965-1970.
12. **Buyss SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, Hartge P, Fagerstrom RM, Ragard LR, Chia D, Izmirlian G, Fouad M, Johnson CC, Gohagan JK, for the PLCO Project Team. Ovarian cancer screening in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. American Journal of Obstetrics and Gynecology, 2005, 193, 1630-1639.**
13. Chang SC, Ziegler RG, Dunn B, Stolzenberg-Solomon R, Lacey J, Huang WY, Schatzkin A, Reding D, Hoover RN, Hartge P, Leitzmann, MF. Association of energy intake and energy balance with postmenopausal breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiology Biomarkers Prevention 2006, 15 (2), 334-341.
14. Chatterjee N, Kalaylioglu Z, Moslehi R, Peters U, Wacholder S. Powerful multilocus tests of genetic association in the presence of gene-gene and gene-environment interactions. The American Journal of Human Genetics 2006, 79, 1002-1016.
15. Chen YH, Chatterjee N, Carroll RJ. Retrospective analysis of haplotype-based case-control studies under a flexible model for gene-environment association. Biostatistics. 2007, May 8. [Epub ahead of print].
16. Crawford ED, Pinsky PF, Chia D, Kramer BS, Fagerstrom RM, Andriole G, Reding D, Gelmann EP, Levin DL, Gohagan JK. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal, and ovarian cancer screening trial. Journal of Urology, 2006, 175, 1286-1290.
17. Cross AJ, Peters U, Kirsh VA, Andriole GL, Reding D, Hayes RB, Sinha R. A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Research, 2005, 65 (24), 11779-11784.
18. *Danforth KN, Hayes RB, Rodriguez C, Yu K, Sakoda LC, Huang WY, Chen BE, Chen J, Andriole GL, Calle EE, Jacobs EJ, Chu LW, Figueroa JD, Yeager M, Platz EA, Michaud DS, Chanock SJ, Thun MJ, Hsing AW. Polymorphic variants in PTGS2 and prostate cancer risk: Results from two large nested case-control studies. Carcinogenesis, 2008, 29(3),568-572.
19. *Danforth KN, Rodriguez C, Hayes RB, Sakoda LC, Huang W-Y, Yu K, Calle EE, Jacobs EJ, Chen BE, Andriole GL, Figueroa JD, Yeager M, Platz EA, Michaud DA, Chanock SJ, Thun MJ, Hsing AW. TNF polymorphisms and prostate cancer risk. Prostate, 2008, 68(4), 400-407.
20. Daugherty SE, Hayes RB, Yeager M, Andriole GL, Chatterjee N, Huang WY, Isaacs WB, Platz EA. RNASEL Arg462gln polymorphism and prostate cancer in PLCO. The Prostate, 2007, 67 (8), 849-854.

2/4/2021

21. Daugherty SE, Platz EA, Shugart YY, Fallin MD, Isaacs WB, Chatterjee N, Welch R, Huang WY, Hayes RB. Variants in the a-methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma. Cancer Epidemiol Biomarkers Prev, 2007, Aug;16(8):1536-1542.
22. Daugherty SE, Shugart YY, Platz EA, Fallin MD, Isaacs WB, Pfeiffer RM, Welch R, Huang WY, Reding D, Hayes RB. Polymorphic variants in a-methylacyl-CoA racemase and prostate cancer. Prostate. 2007, 67:1487-1497.
23. DeKoning HJ, Auvinen A, Sanchez AB, Da Silva FC, Ciatto SD, L, Gohagan JK, Hakama M, Hugosson J, Krranse R, Nelen V, Prorok PC, Schroder FH. Large-scale randomized prostate cancer screening trials: program performance in the european randomized screening for prostate cancer trial and the Prostate, Lung, Colorectal and Ovary Cancer Screening Trial. Int. Journal of Cancer, 2002, 97, 237-244.
24. Dixon LB, Subar AF, Peters U, Weissfeld JL, Bresalier RS, Risch A, Schatzkin A, Hayes RB. Adherence to the USDA Food Guide, DASH Eating Plan, and Mediterranean dietary pattern reduces risk of colorectal adenoma. Journal of Nutrition, 2007, 137(11) 2443-2450.
25. Flood A, Peters U, Jenkins D, Chatterjee N, Subar AF, Church TR, Bresalier R, Weissfeld JL, Hayes RB, Schatzkin A for the Prostate, Lung, Colorectal, Ovarian (PLCO) Project Team. Carbohydrate, glycemic index, and glycemic load and colorectal adenomas in the Prostate, Lung, Colorectal, and Ovarian Screening Study. American Journal of Clinical Nutrition, 2006; 84:1184-92.
26. Ford GM, Hegmann KT, White GL, Holmes EB. Associations of body mass index with meniscal tears. American Journal of Preventive Medicine, 2005, 28 (4), 364-368.
27. Ford ME. Screening and prevention trials step up minority recruitment. Journal of the National Cancer Institute, 1996, 88 (18), 1265-1267.
28. Ford ME, Havstad S, Stallings FL. Recruiting Black men to a clinical trial to evaluate prostate cancer screening. Morbidity and Mortality Weekly Report, 1998, 47, 694-696.
29. Ford ME, Havstad SL, Flickinger L, Johnson CC. Examining the effects of false positive lung cancer screening results on subsequent lung cancer screening adherence. Cancer Epidemiology Biomarkers Prevention, 2003, 12 (1), 28-33.
30. Ford ME, Havstad SL, Tilley BC. Recruiting older African American men to a cancer screening trial (the AAMEN project). In L. Curry and J. Jackson (Eds.), *The science of inclusion: recruiting and retaining racial and ethnic elders in health research*, Washington, DC: The Gerontological Society of America, 2003, 26-34.
31. Ford ME, Havstad MA, Tilley BC. Recruiting older African American men to a cancer screening trial (The AAMEN Project), The Gerontologist, 2003, 43 (1), 27-35.

2/4/2021

32. Ford ME, Havstad SL, Davis SD. A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. Clinical Trials, 2004, 1, 343-351.
33. Ford ME, Randolph V, Hopkins-Johnson L, Eason SL, Havstad S, Jankowski M, Swanson GM, Johnson CC, Vernon SW. Design of a case management approach to enhance cancer screening trial retention among older African American men. Journal of Aging Health, 2004 Nov; 16 (5) Suppl, 39S-57S.
34. Ford ME, Havstad SL, Demers R, Johnson CC. Effects of false-positive prostate cancer screening results on subsequent prostate cancer screening behavior. Cancer Epidemiology Biomarkers Prevention, 2005, 14, 190-194.
35. Ford ME, Havstad S, Vernon SW, Davis SD, Kroll D, Lamerato L, Swanson GM. Enhancing adherence among older African American men enrolled in a longitudinal cancer screening trial. The Gerontologist, 2006, 40 (4), 545-550.
36. Gelmann EP, Chia D, Pinsky PF, Andriole GL, Crawford ED, Reding D, Hayes RB, Kramer BS, Woodrum DL, Gohagan JK, Levin DL. Relationship of demographic and clinical factors to free and total PSA. Urology, 2001, 58(4), 561-566.
37. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial of the National Cancer Institute. Journal of Urology, 1994, 152 (5), 1905-1909.
38. Gohagan JK, Kramer BS, & Greenwald P. Screening for prostate cancer. American Journal of Preventive Medicine, 1994, 10 (4), 245-246.
39. Gohagan J, Prorok P, Kramer B, Cornett J. Screening for ovarian cancer: epidemiological aspects, study design, and target population. In Epithelial Cancer of the Ovary, BMJ Publishing Group, London, UK, 1995, 59-67.
40. Gohagan JK, Prorok PC, Kramer BS, et al. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial of the National Cancer Institute. Cancer Supplement, 1995, 75 (7), 1869-1873.
41. Gohagan JK. PLCO Screening Trial. AUA News, 1997, Jan/Feb, 11.
42. Gohagan JK, Prorok PC, Hayes R, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Controlled Clinical Trials, 2000, 21(6S), 251S-272S.
43. Gohagan JK, Marcus PM, Fagerstrom RM et al. Screening for lung cancer. In: Williams C, ed. Evidence-based Oncology, London: BMJ Books, 2003, 164-71.

2/4/2021

44. Gunter MJ, Hayes RB, Chatterjee N, Yeager M, Welch R, Schoen RE, Yakochi L, Schatzkin A, Peters U. Insulin resistance-related genes and advanced colorectal adenoma. Cancer Epidemiology Biomarkers Prevention 2007; 16(4).
45. Gupta AK, Pinsky P, Rall C, Mutch MG, Schoen RE. Validity and reliability of the endoscopic diagnosis of aberrant crypt foci. Gastroenterology, 2007, 132 (4):A298-A298 Suppl 2.
46. Hartge P, Hayes R, Reding D, Sherman ME, Prorok P, Schiffman M, Buys S. Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors. Am. J Obstet Gynecol, 2000, 83 (5), 1232-1237.
47. Hasson MA, Fagerstrom R, Kahane DC, Walsh JH, Myers MH, Caughman C, Wenzel B, Haralson JC, Flickinger LM, Turner LM. Design and evolution of the data management systems in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials, 2000, 21(6S), 329S-348S.
48. Hayes RB, Reding D, Kopp W, Subar AF, Bhat N, Rothman N, Caporaso N, Ziegler R, Johnson CC, Weissfeld J, Hoover RN, Hartge P, Palace C, Gohagan JK, Etiologic and early marker studies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials, 2000, 21(6S), 349S-355S.
49. Hayes RB, Smith CO, Huang WY, Read Y, Kopp WC. Whole blood cyropreservation in epidemiological studies. Cancer Epidemiology Biomarkers Prevention. 2002, 11, 1496-1498.
50. Hayes RB, Sigurdson A, Moore L, Peters U, Huang WY, Pinsky P, Reding D, Gelmann EP, Rothman N, Pfeiffer RM, Hoover RN, Berg CD for the PLCO Trial Team, Methods for etiologic and early marker investigations in the PLCO Trial. Fundamentals and Molecular Mechanisms of Mutagenesis, 2005.
51. Hou L, Chatterjee N, Huang WY, Baccarelli A, Yadavalli S, Yeager M, Bresalier RS, Chanock SJ, Caporaso NE, Ji BT, Weissfeld JL, Hayes RB. CYP1A1 Val462 and NQO1 Ser 187 polymorphisms, cigarette use and risk for colorectal adenoma. Carcinogenesis 2005, June 26 (6), 1122-1128.
52. Huang WY, Chatterjee N, Chanock S, Dean M, Yeager M, Schoen RE, Hou LF, Berndt SI, Yadavalli S, Johnson CC, Hayes RB. Microsomal epoxide hydrolase polymorphisms and risk for advanced colorectal adenoma. Cancer Epidemiology Biomarkers Prevention 2005, 14(1), 152-157.
53. Huang WY, Berndt SI, Kang D, Chatterjee N, Chanock SJ, Yeager M, Welch R, Bresalier RS, Weissfeld JL, Hayes RB. Nucleotide excision repair gene polymorphisms and risk of advanced colorectal adenoma: XPC polymorphisms modify smoking-related risk. Cancer Epidemiology Biomarkers Prevention 2006, 15(2), 306-311.
54. *Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni

2/4/2021

- JF, Hoover RN, Thomas G, Chanock SJ. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007; (7):870-4. Epub 2007 May 27.
55. Jernigan J. Factors that influence cancer screening in older African American men and women: focus group findings. Community Health, 2001, 24 (3), 1-7.
56. Ji BT, Weissfeld JL, Chow WH, Huang WY, Schoen RE, Hayes RB for the Prostate, Lung, Colorectal and Ovarian Trial Team. Tobacco smoking and colorectal hyperplastic and adenomatous polyps. Cancer Epidemiology Biomarkers Prevention 2006, 15 (5), 897-901.
57. Johnson DB. The effect of abnormal cancer screening test results on health related quality of life. International Journal of Cancer Research 2006, 2 (3); 277-289.
58. Kang D, Andriole GL, Van de Vooren RC, Crawford D, Chia D, Urban DA, Reding D, Huang WY, Hayes RB. Lower Urinary Tract – Risk Behaviours and benign prostatic hyperplasia. British Journal of Urology. 2004, 93 (9); 1241-1245.
59. Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, Albanes D, Andriole GL, Urban DA, Peters U. Supplemental and dietary vitamin E, beta carotene, and vitamin C intakes and prostate cancer risk. 2006, Journal of the National Cancer Institute, 98 (4), 245-254.
60. Kirsh VA, Mayne ST, Peters U, Chatterjee N, Leitzmann MF, Dixon LB, Urban DA, Crawford ED, Hayes RB. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiology Biomarkers Prevention 2006, 15 (1), 92-98.
61. Kirsh VA, Peters U, Mayne ST, Subar AF, Chatterjee N, Johnson CC, Hayes RB. A prospective study of fruit and vegetable intake and risk of prostate cancer. 2007, Journal of the National Cancer Institute, 99(15):1200-1209.
62. Koralek DO, Peters U, Andriole G, Reding D, Kirsh V, Subar A, Schatzkin A, Hayes R, Leitzmann MF. A prospective study of dietary alpha-linolenic acid and the risk of prostate cancer (United States). Cancer Causes Control 2006, 17:783-791.
63. Kramer BS, Gohagan J, Prorok PC, Smart C. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian Cancers. Cancer, 1993, 71 (2), S589-593.
64. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Annals of Internal Medicine, 1993, 119 (9), 914-923.
65. Kramer BS, Gohagan J, Prorok PC. NIH consensus 1994: Screening, Gyn Oncol, 1994, 55, S20-S21.
66. Lacey JV, Greene MH, Buys SS, Reding D, Riley TL, Berg CD, Fagerstrom RM, Hartge P. Ovarian cancer screening in women with a family history of breast or ovarian cancer, Obstetrics and Gynecology, 2006, 108 (5), 1176-1184.

2/4/2021

67. Lafata JE, Simpkins J, Lamerato L, Poisson L, Divine G, Johnson CC. The economic impact of false-positive cancer screens. Cancer Epidemiology Biomarkers Prevention, 2004, 13(12), 2126-32.
68. Lamerato LE, Marcus P, Jacobsen G, Johnson CC. Recruitment in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial: The first Phase of Recruitment at Henry Ford Health System. Cancer Epidemiol Biomarkers Prev, 2008, 17(4):827-833.
69. McFarland EG, Brink JA. Helical CT colonography (virtual colonoscopy): the challenge that exists between advancing technology and generalizability, American Journal of Roentgenology, 1999, 173, 549-559.
70. McFarland EG, Brink JA, Pilgram TK, Heiken JP, Balfe DM, Hirselj D, Weinstock L, Littenberg B. Spiral CT colonography: reader agreement and diagnostic performance with two and three-dimensional image-display techniques. Radiology, 2001, 218 (2), 375-383.
71. McFarland EG, Pilgram TK, Brink JA, McDermott RA, Santillan CV, Brady PW, Heiken JP, Balfe DM, Weinstock LB, Thyssen EP, Littenberg B. CT colonography: multiobserver diagnostic performance. Radiology, 2002, 225, 380-390.
72. McGlynn KA, Sakoda LC, Hu Y, Schoen RE, Bresalier RS, Yeager M, Chanock S, Hayes RB, Buetow KH. Hemochromatosis gene mutations and distal adenomatous colorectal polyps, Cancer Epidemiology Biomarkers Prevention, 2005, 14 (1), 158-163.
73. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, Hsing A, Huang WY, Hayes RB. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Research, 2006, 66 (8), 4525-4530.
74. Millen AE, Subar AF, Graubard BI, Peters U, Hayes RB, Weissfeld JL, Yokochi LA, Ziegler RG; for the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Project Team. Fruit and vegetable intake and prevalence of colorectal adenoma in a cancer screening trial. American Journal of Clinical Nutrition, 2007, 86(6), 1754-64.
75. Miller AB, Yurgalevitch S, Weissfeld JL. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials, 2000, 21(6S), 400S-406S.
76. Miller AB, Madalinska, Church T, Crawford D, Essink-Bot, JL, Goel V, de Koning HJ, Maattanen L, Pentikainen T. Health-related quality of life and cost-effectiveness studies in the european randomised study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary Trial. European Journal of Cancer, 2001, 37, 2154-2160.
77. Moore LE, Huang WY, Chatterjee N, Gunter M, Chanock S, Yeager M, Welch B, Pinsky P, Weissfeld J, Hayes RB. GSTM1, GSTT1, and GSTP1 polymorphisms and risk of advanced colorectal adenoma. Cancer Epidemiology Biomarkers Prevention, 2005, 14(7), 1823-1827.

2/4/2021

78. Morton LM, Wang SS, Bergen AW, Chatterjee N, Kvale P, Welch R, Yeager M, Hayes RB, Chanock SJ, Caporaso NE. DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Pharmacogenetics and Genomics, 2006; 16, 901-910.
79. Moslehi R, Chatterjee N, Church TR, Chen J, Yeager M, Weissfeld J, Heirr D, Hayes RB. Cigarette smoking, N-acetyltransferase genes and the risk of advanced colorectal adenoma. Pharmacogenomics, 2006; 7 (6); 810-829.
80. Mukherjee B, Chatterjee N. Exploiting gene-environment independence for analysis of case-control studies: an empirical Bayes approach to trade off between bias and efficiency. Biometrics, 2007, [Epub ahead of print].
81. O'Brien B, Nichaman L, Browne JEH, Levin, D, Prorok, PC & Gohagan, JK. Coordination and management of a large multicenter screening trial: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Controlled Clinical Trials, 2000, 21(6S), 310S-328S.
82. **Oken MM, Marcus PM, Hu P, Beck TM, Hocking W, Kvale PA, Cordes J, Riley TL, Winslow SD, Peace S, Levin DL, Prorok PC, Gohagan JK for the PLCO Project Team. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Journal of the National Cancer Institute, 2005, 97 (24), 1832-1839.**
83. Ortner ER, Hayes RB, Weissfeld J, Gelmann EP. Effect of homeodomain protein NKX3.1 R52C polymorphism on prostate gland size. Urology, 2006, 67 (2), 311-315.
84. Peters U, Sinha R, Chatterjee N, Subar A, Ziegler RG, Kulldorff M, Bresalier R, Weissfeld JL, Flood A, Schatzkin A, Hayes RB. Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. The Lancet. May 3, 2003, 361, 1491-1495.
85. Peters U, Hayes RB, Chatterjee N, Shao W, Schoen RE, Pinsky P, Hollis BW, McGlynn KA, PLCO Project Team. Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk. Cancer Epidemiology Biomarkers Prevention, April 2004, 13(4), 546-552.
86. Peters U, Chatterjee N, McGlynn KA, Schoen RE, Church TR, Bresalier RS, Gaudet MM, Flood A, Schatzkin A, Hayes RB. Calcium intake and colorectal adenoma in a US colorectal cancer early detection program. American Journal of Clinical Nutrition, 2004, 80, 1358-65.
87. Peters U, Chatterjee N, Yeager M, Chanock SJ, Schoen RE, McGlynn KA, Church TR, Weissfeld JL, Schatzkin A, Hayes RB. Association of genetic variants in the calcium-sensing receptor with risk of colorectal adenoma. Cancer Epidemiology Biomarkers Prevention, December 2004, 13(12), 2181-2186.

2/4/2021

88. Peters U, Chatterjee N, Church TR, Mayo C, Sturup S, Foster CB, Schatzkin A, Hayes RB. High serum selenium and reduced risk of advanced colorectal adenoma in a colorectal cancer early detection program. Cancer Epidemiology Biomarkers Prevention, February 2006, 15 (2), 315-320.
89. Peters U, Foster CB, Chatterjee N, Schatzkin A, Reding D, Andriole GL, Crawford ED, Sturup S, Chanock SJ, Hayes RB. Serum selenium and risk of prostate cancer – a nested case-control study. American Journal of Clinical Nutrition, January 2007, 85 (1), 209-217.
90. Peters U, Leitzmann MF, Chatterjee N, Wang Y, Albanes D, Gelmann EP, Friesen MD, Riboli E, Hayes RB. Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiology Biomarkers Prevention, May 2007, 16 (5), 962-968.
91. Pinsky PF. Estimation and prediction for cancer screening models using deconvolution and smoothing. Biometrics, 2001 June, 57 (2), 389-95.
92. Pinsky PF, Andriole GL, Kramer BS, Hayes RB, Prorok PC, Gohagan JK. Prostate biopsy following a positive screen in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Journal of Urology. March 2005, 173, 746-750; discussion 750-751.
93. Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK. Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer, March 2007.
94. Pinsky PF, Ford M, Gamito E, Higgins D, Jenkins V, Lamerato L, Tenoria S, Marcus P, Gohagan JK. Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Journal of the National Medical Association, 2008, 100(3), 291-298.
95. Pinsky PF, Freedman M, Kvale P, Oken M, Caporaso N, Gohagan J. Abnormalities on chest radiograph reported in subjects in a cancer screening trial. Chest, 2006, 130 (3), 688-693.
96. Pinsky PF, Kramer BS, Crawford ED, Grubb RL, Urban DA, Andriole GL, Chia D, Levin DL, Gohagan JK. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology, 2006, 68 (2), 352-356.
97. Pinsky PF, Kramer BS, Reding D, Buys S. Reported family history of cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. American Journal of Epidemiology, May 2003, 157 (9), 792-799.
98. Pinsky PF, Miller A, Kramer BS, Church T, Reding D, Prorok P, Gelmann E, Schoen RE, Buys S, Hayes RB, Berg CD. Evidence of a healthy volunteer effect in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. American Journal of Epidemiology
99. Pinsky PF, Crawford ED, Kramer BS, Andriole GL, Gelmann EP, Grubb R, Greenlee R, Gohagan JK. Repeat prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. British Journal of Urology International, 99 (4):775-779.

2/4/2021

100. Pinsky PF, Schoen RE, Weissfeld JL, Bresalier RS, Hayes RB, Gohagan JK, Predictors of advanced proximal neoplasia in persons with abnormal screening flexible sigmoidoscopy. Clinical Gastroenterology and Hepatology, March 2003, 1 (2).
101. Pinsky PF, Schoen RE, Weissfeld JL, Kramer B, Hayes RB, Yokochi L for the PLCO Project Team. Variability in flexible sigmoidoscopy performance among examiners in a screening trial. Clinical Gastroenterology and Hepatology, 2005, 3, 792-797.
102. Prorok PC, Byar DP, Smart CR, Baker SG, Connor RJ. Evaluation of screening for prostate, lung and colorectal cancers: The PLC Trial. In Miller AB, Chamberlain J, Dah NE, Hakama M, Prorok PC (eds). Cancer Screening, 1991, 300-320.
103. Prorok PC, Gohagan J, Kramer B. The National Cancer Institute multi-screening trial. Canadian Journal of Oncology, 1994, 4 (1), S98-101.
104. Prorok PC, Potosky AL, Gohagan JK, Kramer BS. Prostate cancer screening: Current issues. In: AB Miller (ed.), Advances in Cancer Screening, Boston: Kluwer Academic Publishers, 1996, 93-112.
105. Prorok PC, Andriole GL, Bresalier R, Buys S, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes R, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken M, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials, 2000, 21(6S), 273S-309S.
106. Purdue MP, Mink PJ, Hartge P, Huang WY, Buys S, Hayes RB. Hormone replacement therapy, reproductive history, and colorectal adenomas: data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial (United States). Cancer Causes and Control, 2005, 16 (8), 965-973.
107. Ristvedt ST, McFarland EG, Weinstock LB, Thyssen EP. Patient preferences for CT colonography, conventional colonoscopy, and bowel preparation. The American Journal of Gastroenterology, 2003, 98(3), 578-585.
108. Schoen RE, Mutch M, Rall C, Dry S, Seligson D, Umar A, Pinsky P. The natural history of aberrant crypt foci. Gastrointest Endosc., 2008 Jan 4 [Epub ahead of print].
109. Schoen RE, Pinsky PF, Weissfeld JL, Bresalier RS, Church T, Prorok P, Gohagan JK. Results of repeat sigmoidoscopy 3 years after a negative examination. JAMA, July 2003, 290 (1), 41-48.
110. Schoen RE, Schragin J, Weissfeld JL, Thaete FL, Evans RW, Rosen CJ, Kuller LH. Lack of association between adipose tissue distribution and IGF-1 and IGFBP-3 in men and women. Cancer Epidemiology Biomarkers Prevention, June 2002, 11, 581-586.

2/4/2021

111. Schoen RE, Weissfeld JL, Juller LH, Thaete FL, Eans RW, Hayes RB, Rosen CJ. Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. Gastroenterology, August 2005, 129 (2), 464-475.
112. Schoen R., Weissfeld J et al. Patient satisfaction with screening flexible sigmoidoscopy, Archives of Internal Medicine, 2000, 160(12), 1790-1796.
113. Schoen RE, Weissfeld JL, Pinsky PF, Riley T. Yield of advanced adenoma and cancer based on polyp size detected at screening flexible sigmoidoscopy. Gastroenterology, December 2006, 131 (6), 1683-1689.
114. *Schumacher FR, Feigelson S, Cox DG, Haiman CA, Albanes D, Buring J, Calle EE, Chanock SJ, Colditz GA, Diver WR, Dunning AM, Freedman ML, Gaziano JM, Giovannucci E, Hankinson SE, Hayes RE, Henderson BE, Hoover RN, Kaaks R, Key T, Kolonel LN, Kraft P, Le Marchand L, Ma J, Pike MC, Riboli E, Stampfer MJ, Stram DO, Thomas G, Thun MJ, Travis R, Virtamo J, Andriole G, Gelmann E, Willett WC, Hunter DJ. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Research, April 2007, 67 (7), 2951-2956.
115. Sherman ME, Lacey JV, Buys SS, Reding DJ, Berg CD, Williams C, Hartge P. Ovarian volume: determinants and associations with cancer among postmenopausal women. Cancer Epidemiology Biomarkers Prevention, August 2006, 15 (8), 1550-1554.
116. Simpson NK, Johnson CC, Ogden S, Gamito E, Trocky N, McGuire C, Martin J, Barrow S, Lamerato L, Flickinger LM, Broski KG, Engelhard D, Hilke C, Bonk J, Gahagan B, Gren L, Childs J, Lappe K, Fouad M, Thompson J, Sullivan D. Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years. Controlled Clinical Trials, 2000, 21(6S), 356S-378S.
117. Sinha R, Peters U, Cross AJ, Kulldorff M, Weissfeld JL, Pinsky PF, Rothman N, Hayes RB and the Prostate, Lung, Colorectal, and Ovarian Cancer Project Team. Meat, meat cooking methods and preservation, and risk for colorectal adenoma. Cancer Research, 2005, 65 (17), 8034-8041.
118. Sit SY, Modugno F, Mill LM, Martin J, Weissfeld JL. Transvaginal ultrasound measurement of endometrial thickness as a biomarker for estrogen exposure. Cancer Epidemiology Biomarkers Prevention, September 2004, 13(9), 1459-1465.
119. Stallings FL, Ford ME, Simpson NK, Fouad M, Jernigan JC, Trauth JM, Miller DS. Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials, 2000, 21(6S), 379S-389S.
120. Stolzenberg-Solomon RZ, Chang SC, Leitzmann MF, Johnson KA, Johnson C, Buys SS, Hoover RN, Ziegler RG. Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. American Journal of Clinical Nutrition, 2006, 83:895-904.

2/4/2021

121. Sturup S, Hayes RB, Peters U. Development and application of a simple routine method for the determination of selenium in serum by octopole reaction system ICPMS, Anal Bioanal Chem, 2005, 381, 386-694.
122. Subar AF, Ziegler RG, Thompson FE, Johnson CC, Weissfeld JL, Reding D, Kavounis KH, Hayes RB. Is shorter always better? Relative importance of questionnaire length and cognitive ease on response rates and data quality for two dietary questionnaires. American Journal of Epidemiology. 2001, 153, (4), 404-409.
123. Tammemagi CM, Freedman MT, Church TR, Oken MM, Hocking W, Kvale PA, Hu P, Riley TL, Ragard L, Prorok PC, Berg CD. Factors associated with small aggressive non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2007, 16(10):2082-2089.
124. Taylor KL, Shelby RA, Schwartz MD, Ackerman JL, LaSalle VH, Gelmann EP, McGuire C. The impact of item order on ratings of cancer risk perception. Cancer Epidemiology Biomarkers Prevention, 2002, 11, 654-659.
125. Taylor KL, Shelby MA, Gelmann E, McGuire C. Quality of life and trial adherence among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Journal of the National Cancer Institute, 2004, 96 (14), 1083-1094.
126. Taylor KL, Cox LS, Zincke N, Mehta L, McGuire C, Gelmann E. Lung cancer screening as a teachable moment for smoking cessation. Lung Cancer, 2007, 56 (1), 125-134.
127. *Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF, Hoover R, Hayes RB, Hunter DJ, Chanock SJ. Multiple loci identified in a genome-wide association study of prostate cancer. Nature Genetics, 2008, 40(3):310-315.
128. Trauth JM, Jernigan JC, Siminoff LA, Musa D, Neal-Ferguson D, Weissfeld J. Factors affecting older African American women's decisions to join the PLCO Cancer Screening Trial. Journal of Clinical Oncology, 2005, 23 (34), 8730-8738.
129. Wang SS, Morton LM, Bergen AW, Lan EZ, Chatterjee N, Kvale P, Hayes RB, Chanock SJ, Caporaso NE. Genetic variation in catechol-O-methyltransferase (COMT) and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Human Genetics, 2007, 122(1), 41-49.
130. Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Chia D, Crawford ED, Kaaks R, Hayes RB. IGF-1 and IGFBP-3: risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. International Journal of Cancer, 2007, Nov;121(10):2267-73.

2/4/2021

131. Weiss JM, Huang W-Y, Rinaldi S, Fears TR, Chatterjee N, Hsing AW, Crawford ED, Andriole GL, Kaaks R, Hayes RB. Endogenous sex hormones and the risk of prostate cancer. *International Journal of Cancer*, 2009 [Epub ahead of print].
132. Weissfeld J, Fagerstrom R, O'Brien B. Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Controlled Clinical Trials*, 2000, 21(6S), 390S-399S.
133. Weissfeld JL, Ling BS, Schoen RE, Bresalier RS, Riley T, Prorok P. Adherence to repeat screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Cancer*, 2002, 94, 2569-76.
134. **Weissfeld JL, Schoen RE, Pinsky PF, Bresalier RS, Church T, Yurgalevitch S, Austin JH, Prorok PC, Gohagan JK for the PLCO Project Team. Flexible sigmoidoscopy in the PLCO Cancer Screening Trial: results from the baseline screening examination of a randomized trial, *Journal of the National Cancer Institute*, 2005; 97 (13), 989-997.**
135. Wendelboe AM, Hegmann KT, Biggs JJ, Cox CC, Portmann AJ, Gildea JH, Gren LH, Lyon JL. Relationships between body mass indices and surgical replacements of knee and hip joints. *American Journal of Preventive Medicine*, 2003, 25(4), 290-295.
136. Wendelboe AM, Hegmann KT, Gren LH, Alder SC, White GL, Lyon JL. Associations between body-mass index and surgery for rotator cuff tendonitis. *The Journal of Bone and Joint Surgery*, 2004; 86-A (4), 743-747.
137. Whiting BR, McFarland EG, Brink JA. Influence of image acquisition parameters on CT artifacts and polyp depiction in spiral CT colonography: in vitro evaluation. *Radiology*, 2000, 217(1), 165-172.
138. *Yeager N, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF, Hoover R, Hunter DJ, Chanock SJ, Thomas G. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. *Nature Genetics*, 2007, 39; 645-649

*CGEMS Project